Abstract
Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 171-174 |
| Number of pages | 4 |
| Journal | Investigational New Drugs |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 1 1995 |
Fingerprint
Keywords
- echinomycin
- metastatic
- sarcoma
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
Cite this
}
A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study. / Gradishar, William J; Vogelzang, Nicholas J.; Kilton, Lary J.; Leibach, Steven J.; Rademaker, Alfred W; French, Suzanne; Benson III, Al B.
In: Investigational New Drugs, Vol. 13, No. 2, 01.06.1995, p. 171-174.Research output: Contribution to journal › Article
TY - JOUR
T1 - A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma - An Illinois cancer center study
AU - Gradishar, William J
AU - Vogelzang, Nicholas J.
AU - Kilton, Lary J.
AU - Leibach, Steven J.
AU - Rademaker, Alfred W
AU - French, Suzanne
AU - Benson III, Al B
PY - 1995/6/1
Y1 - 1995/6/1
N2 - Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.
AB - Echinomycin, a cyclic peptide in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously treated for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m2 administered intravenously, once weekly × 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 treatment cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.
KW - echinomycin
KW - metastatic
KW - sarcoma
UR - http://www.scopus.com/inward/record.url?scp=0028844387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028844387&partnerID=8YFLogxK
U2 - 10.1007/BF00872868
DO - 10.1007/BF00872868
M3 - Article
VL - 13
SP - 171
EP - 174
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 2
ER -